MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8352
-0.0301
-3.48%
Closed 16:00 09/21 EDT
OPEN
0.8640
PREV CLOSE
0.8653
HIGH
0.8962
LOW
0.8100
VOLUME
220.74K
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
0.5552
MARKET CAP
16.55M
P/E (TTM)
-0.5428
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentationsNEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available
GlobeNewswire · 11h ago
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals
GlobeNewswire · 09/14 13:35
Salarius Pharmaceuticals to Present at Upcoming Investor Conferences
Presentations Will Highlight Corporate and Clinical ProgressHOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming investor
GlobeNewswire · 09/10 11:30
2 Conferences Are Going Virtual This Month – One On Cannabis And Another Life Sciences
The coronavirus pandemic has made this an interesting time for the cannabis and life sciences industries.
Benzinga · 09/08 16:12
Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
The following slide deck was published by Salarius Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 09/02 23:00
Salarius Pharmaceuticals to Present During Virtual LD 500 Conference
Webcast presentation scheduled for Tuesday, September 1, 2020HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur
GlobeNewswire · 08/27 15:00
Insider Buys Salarius Pharmaceuticals Stock
A Form 4 filing filed with the SEC on Monday, August 24 showed that Hanish Arnold C bought 4,000 shares of Salarius Pharmaceuticals Inc (NASDAQ:SLRX) at an average price of $0.98. The transaction moved the executive's stake in Salarius Pharmaceuticals to 1
Benzinga · 08/24 15:51
Insider Buys Salarius Pharmaceuticals Stock
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) was trading 0.1% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, August 17 showed that Exec VP Finance CFO Rosenblum Mark J bought 5,000 shares at an average price of $1.00. The t
Benzinga · 08/18 16:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLRX stock price target is 4.433 with a high estimate of 5.00 and a low estimate of 3.800.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 496.94K
% Owned: 2.51%
Shares Outstanding: 19.82M
TypeInstitutionsShares
Increased
3
10.21K
New
6
-247.07K
Decreased
3
60.36K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Director
William McVicar
President/Chief Executive Officer/Director
David Arthur
Chief Financial Officer/Executive Vice President - Finance
Mark Rosenblum
Chief Operating Officer
Kathie Lindemann
Senior Vice President
Nadeem Mirza
Chief Scientific Officer/Director
Bruce McCreedy
Lead Director/Independent Director
Paul Lammers
Independent Director
Tess Burleson
Independent Director
Arnold Hanish
Independent Director
Jonathan Lieber
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average SLRX stock price target is 4.433 with a high estimate of 5.00 and a low estimate of 3.800.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLRX
Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.